D. Kieback

发表

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

John M S Bartlett, Hein Putter, Cornelis J H van de Velde, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Functional characterization of somatic point mutations of the human estrogen receptor alpha (hERalpha) in adenomyosis uteri.

D. Kieback, M. Oehler, H. Greschik, 2004, Molecular human reproduction.

Wild-type p53 suppresses the malignant phenotype in breast cancer cells containing mutant p53 alleles.

I. Runnebaum, T. Friedmann, D. Kieback, 1994, Anticancer research.

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.

John M S Bartlett, Hein Putter, Cornelis J H van de Velde, 2016, Archives of pathology & laboratory medicine.

Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.

O. Olopade, T. Rebbeck, B. Karlan, 2001, Pharmacogenetics.

Effect of prior chemotherapy regimens on the efficacy of endocrine therapy within a German cohort of the TEAM trial

A. Hasenburg, D. Kieback, P. Hadji, 2013, Journal of Cancer Research and Clinical Oncology.

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.

A. Hasenburg, D. Kieback, W. Dornoff, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.

A. Hasenburg, D. Kieback, P. Hadji, 2009, Breast.

Adnexal Masses in Pregnancy

M. C. Vos, G. van de Putte, D. Kieback, 2003, Oncology Research and Treatment.

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

R. Kreienberg, S. Wang-gohrke, A. Godwin, 1999, British Journal of Cancer.

Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial.

A. Hasenburg, D. Kieback, P. Hadji, 2012, Anticancer Research.

Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer.

A. Hasenburg, D. Kieback, J. Salama, 2002, Gynecologic oncology.

Topotecan Chemotherapy in Patients with Breast Cancer and Brain Metastases: Results of a Pilot Study

A. Schindler, G. von Minckwitz, J. Sehouli, 2001, Oncology Research and Treatment.

Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer.

Matthew L. Anderson, S. W. Kim, D. Kieback, 2006, Anticancer research.

Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer

D. Kieback, M. Oehler, M. Rees, 2003, British Journal of Cancer.

A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk.

D. Edwards, N. Weigel, D. Kieback, 2004, The Journal of clinical endocrinology and metabolism.

Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines

R. Kreienberg, I. Runnebaum, D. Kieback, 1994, Human Genetics.

p53 mutant His175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6

R. Kreienberg, I. Runnebaum, D. Kieback, 1994, FEBS letters.

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.

A. Harris, J. Baselga, R. Herbst, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin

R. Kreienberg, R. Moll, I. Runnebaum, 1998, International journal of cancer.

Establishment of new ovarian and colon carcinoma cell lines: differentiation is only possible by cytokeratin analysis.

R. Kreienberg, R. Moll, C. Gerharz, 1994, British Journal of Cancer.

Subcellular localization of accumulated p53 in ovarian cancer cells.

R. Kreienberg, I. Runnebaum, D. Kieback, 1996, Gynecologic oncology.

Molecular aspects of ovarian cancer. Is gene therapy the solution?

R. Ramesh, S. Freeman, D. Kieback, 1999, Hematology/oncology clinics of North America.

Aggressive Management of Recurrent Ovarian Cancer – the Challenge of Individualizing Cancer Therapy Illustrated by a Case Report

A. Hasenburg, D. Kieback, D. Fischer, 2004, Oncology Research and Treatment.

Comparison of Long-term Survival of Cytomegalovirus Promoter versus Rous Sarcoma Virus Promoter-Driven Thymidine Kinase Gene Therapy in Nude Mice Bearing Human Ovarian Cancer

C. Contant, A. Hasenburg, D. Kieback, 1999 .

EDITORIAL Gene Expression Profile in Endometrioid Endometrial Carcinoma

D. Kieback, D. Fischer, 2001 .

Comparative Evaluation of Seven Cell Collection Devices for Cervical Smears

D. Kieback, G. Gitsch, P. Kohlberger, 1999, Acta Cytologica.

A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.

N. McKenna, D. Carney, D. Kieback, 1995, British Journal of Cancer.

Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion.

E. Garrett, N. McKenna, D. Carney, 1995, Cancer research.

Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer.

A. Paulussen, A. Romano, D. Kieback, 2006, Gynecologic oncology.

Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor.

R. Hajek, E. Atkinson, M. Press, 1993, Cancer research.

Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.

D. Kieback, V. Möbus, S. Kaubitzsch, 2007, Anticancer research.

Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer

I. Ramzy, A. Hasenburg, D. Kieback, 2000, Cancer Gene Therapy.

Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50.

J. Chang-Claude, H. Becher, S. Wang-gohrke, 2000, Cancer research.

A Genetic Mutation in the Progesterone Receptor (PROGINS) leads to an increased risk of non-familial breast and ovarian cancer causing inadequate control of estrogen receptor driven proliferation

N. Weigel, D. Kieback, I. Agoulnik, 1998 .

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

C. Verschraegen, A. Kudelka, D. Kieback, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adenovirus-Mediated Thymidine Kinase Gene Therapy for Recurrent Ovarian Cancer: Expression of Coxsackie-Adenovirus Receptor and Integrins αvβ3 and αvβ5

I. Ramzy, A. Hasenburg, D. Kieback, 2002, The Journal of the Society for Gynecologic Investigation: JSGI.

Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up.

I. Ramzy, A. Hasenburg, D. Kieback, 2001, Gynecologic oncology.

Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer.

Matthew L. Anderson, S. W. Kim, D. Kieback, 2006, Anticancer research.

Evaluation of lymph nodes in squamous cell carcinoma of the cervix: touch imprint cytology versus frozen section histology.

A. Hasenburg, D. Kieback, T. Levy, 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Coxsackievirus–adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression

A. Hasenburg, D. Kieback, D. Fischer, 2001, Cancer Gene Therapy.

Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix

C. Verschraegen, A. Kudelka, D. Kieback, 1996, Anti-cancer drugs.

Chicken ovalbumin upstream promoter--transcription factor (COUP-TF) expression in human endometrial cancer cell lines.

M. Tsai, I. Runnebaum, M. Press, 1996, Anticancer Research.

Chicken ovalbumin upstream promoter transcription factor (COUP-TF): an orphan steroid receptor with a specific pattern of differential expression in human ovarian cancer cell lines.

R. Kreienberg, B. O’Malley, M. Tsai, 1993, Gynecologic Oncology.

Functional characterization of somatic point mutations of the human estrogen receptor alpha (hERalpha) in adenomyosis uteri.

D. Kieback, M. Oehler, H. Greschik, 2004, Molecular human reproduction.

Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.

R. Kreienberg, I. Runnebaum, D. Kieback, 1997, Anticancer research.

Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets.

B. O’Malley, R. Kesterson, D. Kieback, 1988, Science.

A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.

C. Verschraegen, A. Kudelka, J. Gutterman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL).

R. Kreienberg, E. Atkinson, I. Runnebaum, 1993, Anticancer research.

Intron 9 retention in gene transcripts suggests involvement of CD44 in the tumorigenesis of ovarian cancer.

R. Kreienberg, I. Runnebaum, E. Stickeler, 1997, Anticancer research.

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.

D. Rea, C. Seynaeve, C. V. D. van de Velde, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment.

I. Ramzy, A. Hasenburg, D. Kieback, 1999, Anticancer research.

Gene Therapy of Ovarian Cancer—State-of-the-Art and Future Perspectives

I. Runnebaum, A. Hasenburg, D. Kieback, 2003 .

Human vitamin D receptor mutations: identification of molecular defects in hypocalcemic vitamin D resistant rickets.

B. O’Malley, D. Kieback, J. Pike, 1989, Advances in experimental medicine and biology.

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

A. Harris, J. Baselga, M. Ranson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathway-based subnetworks enable cross-disease biomarker discovery

Pietro Lio', John M S Bartlett, Philippe Lambin, 2018, Nature Communications.

Clinical evaluation of endocervical prostaglandin E2-triacetin-gel for preinduction cervical softening in pregnant women at term.

D. Kieback, H. Zahradnik, T. Lippert, 1986, Prostaglandins.

Midline intravaginal slingplasty for treatment of urinary stress incontinence: results of an independent audit up to 2 years after surgery

D. Kieback, M. M. Ijland, D. Fischer, 2005, International Urogynecology Journal.

Molecular Mechanisms in Signal Transduction: New Targets for the Therapy of Gynecologic Malignancies

D. Kieback, D. Fischer, B. Gabriel, 2002, Oncology Research and Treatment.

Thoughts on the Cytopathologist and Cell Culture

Anshu, Carlos F. Villamil, M. Bibbo, 1999, Acta Cytologica.

Bilateral Sacrospinous Colposuspension (BSC) for the treatment of vaginal vault prolapse – description of a novel method

D. Kieback, 2019, Pelviperineology.

Contributor Index Volume 43, 1999

Anshu, Carlos F. Villamil, M. Bibbo, 1999, Acta Cytologica.

Modified instruments for mobilization of the ureters and parametrial transsection during radical hysterectomy

D. Kieback, T. Burke, 1995, Annals of Surgical Oncology.

Instrumental vaginal delivery today: forceps delivery versus vacuum extraction

D. Kieback, B. Gern, V. Roemer, 1987 .

Expression of splicing factors in human ovarian cancer.

Dirk G Kieback, Elmar Stickeler, Stefan Stamm, 2004, Oncology reports.

Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer

W. Sauerbrei, D. Kieback, M. Oehler, 2002, Cancer Gene Therapy.

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

Hein Putter, Christos Markopoulos, Annette Hasenburg, 2011, The Lancet.

Network-Based Biomarkers Enable Cross-Disease Biomarker Discovery

Syed Haider, Jianxin Wang, Paul C. Boutros, 2018, bioRxiv.

Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM.

A. Hasenburg, D. Kieback, P. Hadji, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.

H. Putter, D. Ross, K. Bloom, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine

P. Boutros, D. Rea, C. Seynaeve, 2017, npj Breast Cancer.

Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial

D. Rea, C. Seynaeve, C. V. D. van de Velde, 2018, Journal of the National Cancer Institute.

Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine

P. Boutros, D. Rea, C. Seynaeve, 2017, npj Breast Cancer.

p53 gain-of-function mutation in codon 175 is a rare event in human breast cancer.

R. Kreienberg, I. Runnebaum, D. Kieback, 1993, Human molecular genetics.

Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir.

D. Kieback, S. Woo, X. Tong, 1996, Anticancer research.

Post-cesarean adhesions–are they a unique entity?

D. Kieback, M. Stark, G. D. Di Renzo, 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.

N. Harbeck, A. Hasenburg, D. Kieback, 2010, Gynecologic oncology.

Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy.

C. Contant, A. Hasenburg, D. Kieback, 1998, Anticancer research.

Society of gynecologic oncologists position paper: breast cancer care.

P. Escobar, D. Kieback, J. Lucci, 2008, Gynecologic oncology.

Survival after relapse in patients with endometrial cancer: results from a randomized trial. C.L. Creutzberg, W.L.J. van Putten, P.C. Koper, et al., Gynecologic Oncology 89 (2003) 201-209.

D. Kieback, J. Pijnenborg, R. Smit, 2004, Gynecologic oncology.

Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy.

K. Blankenburg, C. Contant, E. Stickeler, 1997, Anticancer research.

Adenovirus-mediated thymidine kinase gene therapy induces apoptosis in human epithelial ovarian cancer cells and damages PARP-1.

D. Kieback, 2009, In vivo.

Adenovirus-mediated thymidine kinase gene therapy and coxsackie adenovirus receptor expression in ovarian cancer cells.

D. Kieback, 2008, Cancer genomics & proteomics.

Persistent adenovirus-mediated thymidine kinase gene expression in ovarian cancer cells increases cell killing efficacy over time.

D. Kieback, D. Fischer, B. Delvoux, 2008, Anticancer research.

Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents.

A. Hasenburg, D. Kieback, S. Woo, 1998, Anticancer research.

In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration.

K. Blankenburg, C. Contant, D. Kieback, 1996, Gynecologic oncology.

Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5.

I. Ramzy, A. Hasenburg, D. Kieback, 2002, Journal of the Society for Gynecologic Investigation.

Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter.

C. Contant, S. Lerner, D. Kieback, 2000, Anticancer research.

European Experience With a Novel Noninvasive Sensor for Intra-Amniotic or Extra-Amniotic Evaluation of Fetal Oxygen Saturation

A. Hasenburg, D. Kieback, D. Grab, 2003, The Journal of the Society for Gynecologic Investigation: JSGI.

p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer

R. Kreienberg, E. Atkinson, I. Runnebaum, 1995, The Lancet.

A mutated progesterone receptor allele is more prevalent in unexplained infertility.

M. Pisarska, D. Kieback, S. Carson, 2003, Fertility and Sterility.

Evidence of androgen receptor expression in lichen sclerosus: an immunohistochemical study.

D. Kieback, G. Gitsch, E. Joura, 1998 .

Comparison of ID 8 MOSE and VEGF-modified ID 8 Cell Lines in an Immunocompetent Animal Model for Human Ovarian Cancer

Matthew L. Anderson, S. W. Kim, D. Kieback, 2008 .

Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients.

E. Atkinson, I. Runnebaum, E. Stickeler, 1998, Anticancer research.

The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter.

C. Contant, Z. Guo, A. Hasenburg, 1998, Anticancer research.

Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in German patients.

R. Kreienberg, I. Runnebaum, S. Maier, 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Cloning, expression analysis and chromosomal localization of the human nuclear receptor gene GCNF

A. Cooney, C. Niederberger, D. Kieback, 1998, FEBS letters.

Platelet sensitivity to a prostacyclin analogue in normal and pathological pregnancy.

D. Kieback, T. Lippert, R. Briel, 1984, Prostaglandins, leukotrienes, and medicine.

[Fetal monitoring sub partu in West Germany. I. Basic data].

D. Kieback, K. Bühler, V. Roemer, 1985, Geburtshilfe und Frauenheilkunde.

Gene expression profile in endometrioid endometrial carcinoma.

D. Kieback, D. Fischer, D. Günter Kieback, 2001, Gynecologic oncology.

Endometrial safety of cross-over treatment with tamoxifen followed by exemestane

N. Harbeck, A. Hasenburg, D. Kieback, 2008 .

Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines.

R. Kreienberg, I. Runnebaum, E. Stickeler, 1997, Anticancer Research.

Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.

J. Verweij, J. Schellens, G. Schwartz, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.

H. Putter, D. Ross, K. Bloom, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.